Hugel可转债转换新增约21.1万股并消除剩余CB潜在 overhang

Hugel, a leading Korean botulinum toxin company, will issue 210,000 new common shares following the exercise of conversion rights by holders of its convertible bonds (CB).
According to the Financial Supervisory Service's electronic disclosure system on the 13th, the conversion price of the newly issued shares is 124,800 won per share, of which 211,140 shares are scheduled to be listed on the KOSDAQ market on the 28th. The conversion amount is approximately 26.3 billion won.
The conversion exhausted the entire unconverted balance of the second-series CB. As a result, the potential dilution volume (overhang) that could arise additionally from the CB has effectively been resolved.
The second-series CB that was exhausted was issued in 2017 when global private equity fund (PEF) Bain Capital acquired Hugel. Some of the volume had already been converted into shares, and with this disclosure, the remaining balance will also be fully converted into common shares.
The market views the exhaustion of the entire CB balance as resolving the overhang burden that investors had long been concerned about. However, analysts note that with approximately 210,000 new shares being additionally listed, dilution of existing shareholders' stakes and the potential release of shares could act as short-term variables for the stock price.
"This conversion represents the materialization of potential volume that already existed, and the future impact on the stock price will depend on who actually holds the converted shares and whether they sell," an industry official said.